BIOPHARMA

Featured image by Megan Woodard/PitchBook News

Weekend Analysis

As big pharma’s next patent cliff looms, biotech investors see dollar signs

Some $180 billion in pharma revenue is going off patent in 2027 and 2028.

Stelara was one of Johnson & Johnson’s star vaccines not long ago, bringing in $11 billion in revenue in 2023. But since generic versions started entering the market earlier this year, Stelara sales have dropped by 43%.

Across the board, from J&J to Pfizer and Eli Lilly, the country’s pharmaceutical giants are facing a patent cliff that could spur M&A as they move to fill out their pipelines and close revenue gaps. Analysts estimate some $180 billion in big pharma revenue is at risk by 2030. Pfizer alone has predicted a revenue loss of $17-18 billion by 2030 as a direct result of patent expirations of key drugs.

“It’s a big, big problem for the big boys of our industry,” said Ross Morton, managing partner at Nodenza Capital Partners, a venture firm focused on biotech.

This article appeared as part of The Weekend Pitch newsletter. Subscribe here.

Historically, patent cliffs have been a respite for slow M&A cycles. Pharmaceutical companies’ own R&D is usually far from enough to generate the needed additional revenue, so they turn to acquisitions of smaller companies with newly approved or nearly approved drugs to satisfy their shareholders.

For VCs hungry for liquidity in a stalled IPO market and early-stage companies struggling to land financing, this patent cliff could be a game-changer. But they still face the huge roadblocks, including high interest rates, supply chain uncertainty and softening biotech valuations, that have been holding back Big Pharma from making the usual blockbuster deals.

There were 23 acquisitions in biopharma in the first two quarters of 2025. Only one, J&J’s $14.6 billion acquisition of Intracellular Therapies, crossed the 11-figure mark.

“It is just so difficult to be sure of valuations when there’s that volatility,” said Nicole Daley, a partner at A&O Shearman’s M&A practice. Buyers are still hesitant to pull the trigger on large deals, although therapies are experiencing much more buyer interest, she added.

Biotech equities are trading at significant discounts from a year ago, which is rippling across the industry. Buyers are reluctant to agree to high prices, and startups are increasingly accepting flat and down rounds. The share of deal value in biotech occurring at a flat or valuation step-down rose from 10% in 2023 to 25% so far this year, according to PitchBook data.

In biotech, where a sizable portion of dry powder comes from funds that invest across small-cap public equities and large-cap privately-held companies, the discounted public markets are luring investors and leaving startups with less leverage to negotiate terms.

“We’ve done maybe one private investment so far this year,” said Nimish Shah, who invests in biotech out of Venrock’s biotech and life sciences arm, VHCP. “We’re much more focused on the public side because there’s a lot of stocks trading at cash.”

With federal funding uncertain for early-stage biotech research and investors pulling back, startup fundraising has been challenging. So, the patent cliff may bring some respite there, too: more strategic corporate investors may come to the table, even negotiating early partnerships with promising therapeutics.

Featured image by Megan Woodard/PitchBook News

Learn about our editorial standards.